Department of radiation oncology, Institut Curie, Paris-Orsay, 26 rue d'Ulm, 75005 Paris, France.
Department of radiation oncology, Institut Curie, Paris-Orsay, 26 rue d'Ulm, 75005 Paris, France.
Cancer Radiother. 2021 May;25(3):254-258. doi: 10.1016/j.canrad.2020.09.001. Epub 2021 Jan 2.
The use of IMRT for the treatment of breast cancer has been growing considerably in our institution since 2009. Alternatively, helical tomotherapy (HT) using a field width of 2.5 and 5cm (HT_FW_5), volumetric-modulated arc therapy (VMAT), or proton therapy with pencil-beam scanning (PT-PBS) have also been used to reduce treatment duration or optimize organ-at-risk (OAR) sparing. The purpose of this study was to compare the 4 treatment modalities available at our site.
We studied 10 patients treated for breast cancer with lymph node involvement. The prescribed dose was 51.8Gy to the breast with a simultaneous integrated boost up to 63Gy, and 50.4Gy to lymph nodes in 28 fractions. The CTV was delineated according to ESTRO Guidelines. Dosimetric planning in routine clinical practice was performed using HT_FW_2.5. The approved clinical plan was compared to the 3 other plans. Dosimetric goals for PTV coverage were D95%≥95% and D2%≤107% of the prescribed dose. Mean and maximum doses to OAR were recorded.
HT_FW_5 and VMAT plans ensure equivalent or even better PTV coverage compared to the initial clinically approved plan but at the cost of poorer OAR sparing. PT_PBS plans showed that an excellent PTV coverage can be maintained with significantly lower doses to OAR.
HT_FW_5 and VMAT plans allow a significant reduction of treatment duration and can be a good alternative to HT_FW_2.5 for specific populations. HT_FW_2.5 could be chosen for patients at higher risk of side effects. In addition, PT_PBS should be considered in the near future as it has been shown to have a major potential benefit to lower the risk of side effects with the same level of PTV coverage.
自 2009 年以来,我院在治疗乳腺癌方面越来越多地采用调强放疗(IMRT)。此外,还使用了 2.5cm 和 5cm 射野宽度的螺旋断层放疗(HT_FW_5)、容积调强弧形治疗(VMAT)或笔形束扫描质子治疗(PT-PBS)来缩短治疗时间或优化危及器官(OAR)的保护。本研究旨在比较本单位可用的 4 种治疗方式。
我们研究了 10 例接受保乳手术联合淋巴结清扫术治疗的乳腺癌患者。处方剂量为 51.8Gy 至乳房,同时进行 63Gy 的同步整合提升,28 次分割至淋巴结 50.4Gy。CTV 根据 ESTRO 指南进行勾画。在常规临床实践中进行剂量学规划时,使用 HT_FW_2.5。比较了经批准的临床计划与另外 3 个计划。PTV 覆盖的剂量学目标是 D95%≥95%,D2%≤107%的处方剂量。记录了 OAR 的平均和最大剂量。
HT_FW_5 和 VMAT 计划与最初的临床批准计划相比,可以确保更好或甚至更好的 PTV 覆盖,但代价是 OAR 保护更差。PT_PBS 计划表明,可以通过显著降低 OAR 的剂量来维持良好的 PTV 覆盖。
HT_FW_5 和 VMAT 计划可以显著缩短治疗时间,对于特定人群来说,可以作为 HT_FW_2.5 的替代方案。HT_FW_2.5 可以为副作用风险较高的患者选择。此外,PT_PBS 应该在不久的将来被考虑,因为它已经显示出具有降低副作用风险的巨大潜力,同时保持相同水平的 PTV 覆盖。